Anpac Bio-Medical Presents 'Cancer Differentiation Analysis' Research at Nobel Laureate Cancer Research Summit
- Wall Street ends sharply lower in broad sell-off
- China Property Titan Evergrande (EGRNF) Collapses to 11-Year Lows, Analysts Wary of Domino Effect
- Apple (AAPL) iPhone 13 Has Strong Start with Positive Mix Skew - JP Morgan
- Oil falls 2% on risk aversion, dollar strength
- Pfizer (PFE), BioNTech (BNTX) Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Anpac Introduces 'Breakthrough' Early Cancer Detection 'Blood Biopsy'
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SACRAMENTO, Calif., May 13, 2015 /PRNewswire/ -- Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and Scientist Dr. Chris Yu this week presented what event organizers published as, "very promising" and "breakthrough" early cancer detection technology research results at the "2015 Nobel Prize Laureate Summit on Biomedical Science: Frontiers in Cancer Research" (NPLS) in Tianjin, China.
The NPLS was the first meeting of five Nobel Laureate Prize winners and the 20 top cancer researchers in the world, gathering for an unprecedented exchange of research results and advances related to cancer identification, diagnosis, and treatment.
An accomplished inventor with over 200 patent applications (100 related to leading-edge cancer research/diagnostics), as well as a member of the American Society of Clinical Oncologists (ASCO), Dr. Yu was welcomed by Summit organizers to share Anpac's innovative "Cancer Differentiation Analysis" (CDA) technology results; revealing Anpac's CDA effectively reinventing cancer screening and early cancer detection, through simple, standard, non-invasive blood tests – known as "Blood Biopsies"-- and Anpac CDA medical devices.
Anpac's CDA technology essentially executes for patients and doctors "Blood Biopsies", which research reveals quickly, efficiently, and dramatically improves cancer detection sensitivity and specificity-- without producing any side effects in patients.
In other words, Anpac's CDA diagnostics can identify threatening cancer cells – and the type of cancer cells (or where they are located in the body) – often before those cells become or grow into Stage 1+ tumors (or potentially even forming into tumors in the first place).
Comprehensive research validity data from nearly 20,000 cases indicate Anpac's CDA diagnostics far exceed existing or competing technologies - revealing a sensitivity and specificity rate range of 70%-85% for over ten different types of cancer, with the ability of early stage detection for most of them.
NPLS organizers list the outline of Dr. Yu's research in the Nobel Prize Laureate Summit Research Paper Compilation as: A New Generation Cancer Diagnostic Technology with High Sensitivity and Specificity, Fast Detection Speed, No Side Effects, Ability for Early Diagnosis, and Cost Efficiency. And it concludes the research summary with, "CDA technology is a game-changing, effective approach in detecting a number of cancer sites at an early stage with the potential to resolve several existing issues in the field of cancer diagnostics."
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/anpac-bio-medical-presents-cancer-differentiation-analysis-research-at-nobel-laureate-cancer-research-summit-300083285.html
SOURCE Anpac Bio-Medical Science Company, Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ecolab Named Among the Most Engaged Companies in the World’s Largest Corporate Sustainability Initiative
- First Trust Energy Infrastructure Fund Declares its Monthly Common Share Distribution of $0.0625 Per Share for October
- Prevalence of Online Travel Agencies has Potential to Impact Travel Arrangement and Reservation Businesses | Monitor Industry Risk with BizVibe
Create E-mail Alert Related CategoriesPress Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!